KCAS Bioanalytical & Biomarker Services

kcasbio.com

KCAS Bioanalytical & Biomarker Services is a contract laboratory with 39+ years of bioanalytical expertise. Centrally located in Kansas City, KCAS provides small- and large-molecule PK, immunogenicity, and biomarker analysis operating a variety of equipment platforms to service a wide range of therapeutic areas. KCAS’ team leverages a highly scientific staff with an average tenure in the field of bioanalysis/biomarker analysis of 22 years to provide clients of all sizes with expertise in robust assay development, validation, and sample analysis under fit-for-purpose Non-GLP, GLP, and GCP conditions for discovery, preclinical and clinical studies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

SYGNATURE DISCOVERY TO DEPLOY IKTOS’S AI FOR DRUG DESIGN SOFTWARE MAKYA™

Iktos | May 11, 2022

news image

Iktos, a leading integrated drug discovery CRO headquartered in Nottingham, UK, with expertise across a range of therapeutic and biological target classes today announced a collaboration agreement in AI for new drug design. Under the 3-year agreement, Sygnature will deploy Iktos’ de novo generative design software Makya™, which will be used by Sygnature scientists to facilitate rapid and efficient design of novel compounds and accelerate hit-to-lead/lead optimisation, ...

Read More

INTRAVACC RECEIVES US NIH/NIAID CONTRACT TO DEVELOP ENTEROVIRUS D68 VACCINE

Intravacc | September 08, 2020

news image

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract with base and options that may total US$9.4 million from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic vaccine against enterovirus D68 (EV D68). EV D68 is a respiratory virus that can cause childhood paralysis, Acute Flaccid Myelitis (...

Read More

BUSINESS INSIGHTS

CRESCITA SIGNS EXCLUSIVE 8-COUNTRY LICENSING AGREEMENT WITH EGIS PHARMACEUTICALS FOR PLIAGLIS®

Crescita Therapeutics | December 13, 2021

news image

Crescita Therapeutics Inc. a growth-oriented, innovation-driven Canadian commercial dermatology company, is pleased to announce that it has signed an exclusive commercialization and supply agreement with Egis Pharmaceuticals PLC a leading generic pharmaceutical company in Central Eastern Europe for the rights to Pliaglis in eight countries comprising Hungary, Bulgaria, Czech Republic, Slovakia, Poland, Russia, Latvia and Lithuania. Under the terms of the agreement, Crescita will r...

Read More

PHARMACY MARKET

MALLAX ACQUIRES SANA PHARMA MEDICAL, ESTABLISHING A NEW NORDIC PHARMACEUTICAL PLATFORM

Mallax | July 05, 2021

news image

Mallax Pharmaceuticals AB has acquired Sana Pharma Medical AS, forming a new Nordic pharmaceutical platform. SPM, founded in Norway in 2014, is a rapidly growing OTC company with complete pharmaceutical infrastructure and Nordic distribution coverage. With the well-established brands such as Lunixen and Sedix and additional products based on the chemical melatonin, the Company has a leading position in the fast-growing sleep and anxiety sector. SPM is a well-resourced platform wit...

Read More
news image

BUSINESS INSIGHTS

SYGNATURE DISCOVERY TO DEPLOY IKTOS’S AI FOR DRUG DESIGN SOFTWARE MAKYA™

Iktos | May 11, 2022

Iktos, a leading integrated drug discovery CRO headquartered in Nottingham, UK, with expertise across a range of therapeutic and biological target classes today announced a collaboration agreement in AI for new drug design. Under the 3-year agreement, Sygnature will deploy Iktos’ de novo generative design software Makya™, which will be used by Sygnature scientists to facilitate rapid and efficient design of novel compounds and accelerate hit-to-lead/lead optimisation, ...

Read More
news image

INTRAVACC RECEIVES US NIH/NIAID CONTRACT TO DEVELOP ENTEROVIRUS D68 VACCINE

Intravacc | September 08, 2020

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract with base and options that may total US$9.4 million from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic vaccine against enterovirus D68 (EV D68). EV D68 is a respiratory virus that can cause childhood paralysis, Acute Flaccid Myelitis (...

Read More
news image

BUSINESS INSIGHTS

CRESCITA SIGNS EXCLUSIVE 8-COUNTRY LICENSING AGREEMENT WITH EGIS PHARMACEUTICALS FOR PLIAGLIS®

Crescita Therapeutics | December 13, 2021

Crescita Therapeutics Inc. a growth-oriented, innovation-driven Canadian commercial dermatology company, is pleased to announce that it has signed an exclusive commercialization and supply agreement with Egis Pharmaceuticals PLC a leading generic pharmaceutical company in Central Eastern Europe for the rights to Pliaglis in eight countries comprising Hungary, Bulgaria, Czech Republic, Slovakia, Poland, Russia, Latvia and Lithuania. Under the terms of the agreement, Crescita will r...

Read More
news image

PHARMACY MARKET

MALLAX ACQUIRES SANA PHARMA MEDICAL, ESTABLISHING A NEW NORDIC PHARMACEUTICAL PLATFORM

Mallax | July 05, 2021

Mallax Pharmaceuticals AB has acquired Sana Pharma Medical AS, forming a new Nordic pharmaceutical platform. SPM, founded in Norway in 2014, is a rapidly growing OTC company with complete pharmaceutical infrastructure and Nordic distribution coverage. With the well-established brands such as Lunixen and Sedix and additional products based on the chemical melatonin, the Company has a leading position in the fast-growing sleep and anxiety sector. SPM is a well-resourced platform wit...

Read More